Ticker brief
TRAX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
23
authors 14d
15
crowd 14d
+0.0σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-08 → 2026-10-16 · now +0.40 (−1 bearish … +1 bullish)
Who spoke15
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PersimmonTI | A | +0.79 | 2 | +0.40 |
| @OzmosiHealth | C | · | 2 | +0.25 |
| @AlertsAndNews | C | -3.92 | 2 | +0.28 |
| @StockSwingAlert | C | -1.17 | 2 | +0.55 |
| @BioStocks | C | -1.77 | 2 | +0.17 |
| @DekmarTrades | C | -0.59 | 2 | +0.33 |
| @Briefingcom | B | -2.26 | 2 | +0.53 |
| @BiotechCH | B | +1.42 | 2 | +0.40 |
| @ClassicRoy | C | -1.10 | 1 | +0.00 |
| @zohmbastic | C | -2.94 | 1 | +0.40 |
| @tenet_research | C | -1.23 | 1 | +0.00 |
| @TENETTRADEGROUP | C | -0.65 | 1 | +0.00 |
| @TradeIdeas | C | -1.80 | 1 | +0.00 |
| @Quantumup1 | C | +0.10 | 1 | +0.40 |
| @BiopharmIQ | B | · | 1 | +0.00 |
Recent signals23of 23 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @BiotechCH | +0.30 | Highlights encouraging cross-indication data and upcoming catalysts for three biotech firms. | · | tweet ↗ |
| 2026-10-16 | @BiotechCH | +0.50 | TRAX and ARGX reported positive celiac-disease trial data ahead of a November meeting. | · | tweet ↗ |
| 2026-10-15 | @BiopharmIQ | +0.00 | The post summarizes opening biotech moves and associated regulatory or clinical events. | · | tweet ↗ |
| 2026-10-15 | @BioStocks | -0.15 | TRAX announced a $200 million PIPE priced at $32.75 per share. | · | tweet ↗ |
| 2026-10-13 | @Quantumup1 | +0.40 | Canaccord raised TRAX's target to $60 from $50 and reiterated Buy after positive trial data. | · | tweet ↗ |
| 2026-10-12 | @TradeIdeas | +0.00 | Flags an AI scanner signal on TRAX without describing its direction. | · | tweet ↗ |
| 2026-10-12 | @OzmosiHealth | +0.50 | First Tracks announced positive topline results in a celiac-disease study. | · | tweet ↗ |
| 2026-10-12 | @DekmarTrades | +0.15 | Lists the morning's favored news-driven stocks without a concrete entry. | · | tweet ↗ |
| 2026-10-12 | @AlertsAndNews | +0.55 | Reports statistically positive biopsy results and no serious adverse events in 32 patients. | · | tweet ↗ |
| 2026-10-12 | @TENETTRADEGROUP | +0.00 | Premarket-movers list provides names but no visible direction or magnitude in the text. | · | tweet ↗ |
| 2026-10-12 | @tenet_research | +0.00 | Lists premarket movers without performance figures or directional details. | · | tweet ↗ |
| 2026-10-12 | @Briefingcom | +0.55 | First Tracks said ANB033 met key Phase 1b celiac-disease endpoints and reduced intestinal damage. | · | tweet ↗ |
| 2026-10-12 | @Briefingcom | +0.50 | Lists the largest premarket gaps, led by TRAX and CCC higher and PXED lower. | · | tweet ↗ |
| 2026-10-12 | @DekmarTrades | +0.50 | First Tracks Biotherapeutics reports positive top-line ANB033 results in a celiac-disease study. | · | tweet ↗ |
| 2026-10-12 | @StockSwingAlert | +0.70 | Celebrates TRAX reaching a new high, up 55%, after the move. | · | tweet ↗ |
| 2026-10-12 | @BioStocks | +0.50 | Reports statistically significant positive top-line ANB033 celiac-study results. | · | tweet ↗ |
| 2026-10-12 | @PersimmonTI | +0.70 | Reports statistically significant positive top-line celiac-study results with no safety signals. | · | tweet ↗ |
| 2026-10-12 | @StockSwingAlert | +0.40 | Reports positive top-line study results for ANB033 in celiac disease. | · | tweet ↗ |
| 2026-10-11 | @AlertsAndNews | +0.00 | First Tracks Biotherapeutics will release Phase 1b cohort data on October 12 at 8:30 a.m. ET. | · | tweet ↗ |
| 2026-10-11 | @OzmosiHealth | +0.00 | Announces Oct. 12 topline data from cohort 1 of an ANB033 Phase 1b celiac-disease trial. | · | tweet ↗ |
| 2026-10-11 | @PersimmonTI | +0.10 | Reports the scheduled October 12 Phase 1b celiac top-line data release and webcast. | · | tweet ↗ |
| 2026-10-09 | @zohmbastic | +0.40 | Wells Fargo raised First Tracks Biotherapeutics' target to $62 from $55. | · | tweet ↗ |
| 2026-10-08 | @ClassicRoy | +0.00 | Lists instruments for a 1 p.m. trading lineup without providing direction. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.